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Abstract
IMPORTANCE Primary outcome change could threaten the validity of a clinical trial; however,
evidence about the consequences on the reported intervention effect size is unclear.
OBJECTIVES To examine the status of randomized clinical trials whose primary outcome changed
between trial registration and publication and to quantify the association of this change with the
reported intervention effect size.
DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study on the primary report of
randomized clinical trials with clear prospectively registered primary outcomes, PubMed and Embase
were searched for articles published between January 1, 2011, and December 31, 2015. The search
was conducted in January 2016, identifying randomized clinical trials and the combination of
keywords and text words related to registry.
MAINOUTCOMES ANDMEASURES Based on the developed approach, trials were classified as
having primary outcome change when there was a major discrepancy between the registered and
published primary outcomes. Intervention effect was estimated or recalculated using the odds ratio
(OR) for each comparison. Each component OR is structured so that an OR is less than 1 if the
intervention group has a more favorable result than the control group. The ratio of ORs (ROR), which
is the summary OR for trials with primary outcome change divided by those without, and its 95% CI
were calculated, with a value less than 1 indicating a larger reported intervention effect size in trials
with primary outcome change than those without.
RESULTS Among 29 749 searched articles (28 810MEDLINE and 939 Embase), 1488 articles were
randomly selected for review. Of 389 trials with clear primary outcomes prospectively described in
the registry (416 outcomes reported), 33.4% (130 of 389) of trials had at least 1 primary outcome
change. Most (66 of 130) of the changes were either not reporting or omitting the primary outcome.
In total, 338 trials (365 outcomes and 487 comparisons) were available for quantitative analysis on
the reported intervention effect size bias assessment. Compared with those without primary
outcome change, trials with primary outcome change showed a 16% (pooled ROR, 0.84; 95% CI,
0.73-0.96) larger reported intervention effect size. The result persisted after adjustment for
potential confounders (ROR, 0.81; 95% CI, 0.71-0.93) and other sensitivity and subgroup analyses.
CONCLUSIONS ANDRELEVANCE Results of this study suggest that inconsistencies between
registered and published primary outcomes of clinical trials are common, and trials with primary
outcome change are likely to have a larger intervention effect than those without.
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Introduction
Randomized clinical trials (RCTs) have a crucial role in assessing the efficacy and safety of a treatment
and in advancingmedical knowledge.1 Clinical trials of investigational medicinal products have been
legally required to be registered before participant enrollment since January 5, 2004; furthermore,
to improve transparency of results, the International Committee ofMedical Journal Editorsmember
journals have required since January 7, 2005, that for publication clinical trials of any intervention
should be preregistered.2 Registering a trial is mostly free, and options include ClinicalTrials.gov, EU
Clinical Trials Register, and International Standard Randomized Controlled Trial Number (ISRCTN)
register. Although the reported information differs between registries, a clearly defined and
prespecified primary outcome is an important element.3,4 Discrepancies between registered and
published outcomesmay imply selective outcome reporting based on significant P values.5,6 This
practice could threaten the validity of clinical trials by producing conclusions that maymislead
physicians and policy makers.6-8
Although it is well recognized that registries are important tools to reduce the risk of selective
reporting of outcomes, Jones et al7 found that consistency between planned and published
outcomes varied substantially among 27 eligible studies, with a median consistency proportion of
31% (interquartile range, 17%-45%). Similarly, another study9 analyzing all interventional trials
registered on ClinicalTrials.gov from 1999 to 2012 showed that 32% of trials had their primary
outcomes altered between the listed study start and completion dates. However, previous studies in
this area have focused on specific design characteristics (eg, pain or continuous outcomes) and have
not attempted to quantify towhat extent a primary outcome changewill alter the invention size that
is being estimated.
The objectives of this study were 2-fold. The first objective was to estimate the proportion of
RCTs that had a primary outcome change, without restriction by journals, diseases, or registry
entries. A second objective was to quantify the consequences associated with primary outcome
change on the reported intervention effect size.
Methods
This study followed the Strengthening theReporting ofObservational Studies in Epidemiology (STROBE)
reporting guideline for cross-sectional studies. The study was not submitted for institutional review
board approval because all data are publicly available.
Search Strategy
In this cross-sectional study, we studied the primary report of registered RCTs published between
January 1, 2011, andDecember 31, 2015. A searchwas conducted in January 2016 using the suggested
filters from the Cochrane Collaboration (MEDLINE via PubMed) and the BMJ Evidence Centre
(Embase via Ovid) for identifying RCTs and the combination of keywords and text words related to
registry. No restrictions by journal, disease, or outcome type (ie, continuous or dichotomous
outcome) were applied except that reports had to be in English.
We then randomly selected 5% of the retrieved records from each year. Details of the search
strategy and sampling method are listed in eTables 1, 2, and 3 in the Supplement, and our study
protocol was registered on PROSPERO.10
Study Selection and Eligibility
Articles were screened for relevance by title and abstract and then by the full text to identify primary
trial reports. During this process, one of us (T.C.) excluded duplicate publications, protocol studies
and analysis plans, system reviews or meta-analyses, and feasibility, pilot, or phase 1 studies, as well
as ancillary studies (eg, subgroup analyses, exploratory analyses, secondary outcome analyses,
preliminary results, interim analyses, post hoc analyses, pooled analyses, cost-effectiveness
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analyses, andmechanism research). Next, for each published trial report, we identified the
registration number via published articles or clinical trial registries (ClinicalTrials.gov, ISRCTN register,
or country-specific registries). We only included trials that were registered before study completion
and gave a clear description of the primary outcome in the registry. Two of us (T.C. and R.Q.) checked
the full-text articles in the next 2 processes.
Data Extraction and Risk of Bias (Quality) Assessment
We assigned a unique identification number to each trial included in this study. Data were extracted
using a standardized extraction form. For published articles, we extracted the publication
information (eg, author name and year of publication) and study characteristics, including study
design (eg, noninferiority, superiority, or equivalence), sample size for each group, randomization
method (eg, cluster or individual), and type of outcome (eg, time to event, binary, or continuous). For
registered information, we extracted the following information: start and end dates of participant
enrollment, registration date, the last amendment date, originally registered primary outcomes, and
amended outcomes (if applicable).
The risk of bias (RoB) for each trial was assessed by the RoB tool as recommended by the
Cochrane Collaboration. Overall RoB was assessed as low risk (low for all Cochrane Collaboration
components), high risk (high for1 Cochrane Collaboration component), or unclear risk (unclear for
1 Cochrane Collaboration component). Other RoB items included intent-to-treat (ITT) status, trial
centers, and source of funding. We defined and classified these items according to published
references as follows: deviation from ITT principle (ie, ITT, modified ITT, or no ITT/unknown),11 trial
centers (ie, multiple centers or single center),12 and source of funding (ie, public funding, cofinanced,
for-profit funding, not funded, or not reported) (with not-for-profit funding and not funded
considered high risk).13
Outcome of Interest
Amajor discrepancy was defined if the registered and published primary outcomes were different or
were assessed at a different time point. This definition is according to a modified classification by
Chan et al.6 Specifically, the following were consideredmajor discrepancies: (1) a prespecified
primary outcome in the trial registration protocol was subsequently reported as a secondary
outcome in the final published article; (2) The published primary outcomewas described as a
secondary outcome in the registry; (3) The prespecified primary outcomes in the trial registration
were either omitted or not reported or labeled from the published article; (4) a new primary outcome
was introduced in the published article (eg, an outcome that does not appear at all in the registry but
is introduced as primary in the article, or one of the components changed among a composite
outcome); and (5) the timing of assessment of the primary outcome in the registered protocol and
published article differed.
Inconsistencies were independently identified by 2 of us (T.C. and C.L.), and disagreements
were resolved by discussion until consensus (κ coefficient, 0.92; 95% CI, 0.88-0.96). If changes to
the registered primary outcomeweremade, they were further reviewed by another one of us (V.C.),
and disagreements were resolved by consensus.
Statistical Analysis
Categorical variables were described by frequencies and percentages and quantitative variables by
medians and ranges. We used the κ coefficient to determine the degree of agreement between
reviewers.
To quantify overall the consequences associated with primary outcome change on the reported
intervention effect size across different types of outcomes, we assumed relative risk, hazard ratio,
and odds ratio (OR) to be the samemeasure. This strategy has been used in publishedmeta-analyses
of observational studies.14,15 In our study, we considered ORs to be a common estimate, but
heterogeneity by different types of outcomes was explored in subgroup analyses. For continuous
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outcomes, we converted them to ORs according to themethod by Hasselblad and Hedges by
multiplying the standardizedmean differences and their SEs by 1.81 to calculate the log ORs and the
corresponding SEs.16
For each comparison, we estimated the OR between the intervention group and the control
group. Where necessary, we inverted the effect size so that each comparison was indicated by an OR
less than 1 if the intervention group had amore favorable result than the control group.
Because an enrolled trial may contribute 2 or more comparisons due tomultiple groups and/or
outcomes, we used a linear mixed model with the log ORs of each comparison as the dependent
variable, primary outcome change as a fixed effect, and study identification number as a random
effect after weighting the inverse variation of the log OR of each comparison. Differences are
presented by estimating the ratio of ORs (ROR) after anti–log transformation. The ROR is the
summary OR for trials with primary outcome change divided by those without, with a value less than
1 indicating a larger reported intervention effect size in trials with primary outcome change than
those without. To test the robustness of our study, we conducted 4 sensitivity analyses. First was a
mixedmodel with adjustments for trial characteristics (ie, deviation from ITT principle, study design,
trial centers, type of comparator, randomization method, type of outcome, source of funding, and
RoB). Second was a mixed model using primary outcome change based on reviewer 1 assessment
only or reviewer 2 assessment only. Third, we repeated the mixed model but excluded trials in turn
with (1) different levels of RoB (low risk, high risk, or unclear risk), (2) different type of outcomes
(time to event, binary, or continuous), and (3) multiple outcomes and/or multiple groups. Fourth was
a mixedmodel with the inverse variation of the log OR as additional covariates rather than weights.
We also carried out subgroup analyses according to prespecified characteristics. These included
deviation from ITT principle, study design, trial centers, randomizationmethod, type of outcome,
source of funding, and overall RoB.
All data analyses were performed using statistical software (SAS, version 9.4; SAS Institute Inc).
P values were 2 tailed, and P < .05 was considered statistically significant.
Results
Among 29 749 searched articles (28 810MEDLINE and 939 Embase), 1488 articles were randomly
selected for review. After excluding 864 reports by reviewing the titles and abstracts, we identified
624 potentially eligible publications. Of them, 65 were further excluded after reading through the
full text. After comparing the remaining 559 publications with online registry, we found that 4 trials
(0.7%) were not registered, 92 trials (16.5%) trials were registered after completion of the study, and
74 trials (13.2%) were registered with no description or unclear description of the primary outcome.
Figure 1 shows the screening process for both published RCTs and registry records.
Prevalence of PrimaryOutcome Change and Its Type
Of 389 trials with clear primary outcomes prospectively described in the registry (416 outcomes
reported), 33.4% (130 of 389) of trials had at least 1 primary outcome change. Among those studies
with primary outcome change, we found that the most common discrepancy was either omission or
not reporting or labeling a registered primary outcome (66 of 130). This was followed by publication
of a new outcome (40 of 130), which included 9 composite outcomes with component changes;
different timing of assessment in the article and the registry (17 of 130); a registered primary outcome
reported as a secondary outcome in the article (6 of 130); and the published primary outcome
registered as a secondary outcome (1 of 130). The detailed classification for those trials with primary
outcome change and the type of change are listed in eTable 4 in the Supplement.
Association of PrimaryOutcome ChangeWith Intervention Effect
To quantify the consequences of the change in primary outcome on the reported intervention effect
size, we calculated theOR for each trial. Of the 389 trials, 22 did not report a primary outcome in the
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publication, and 29 did not have a reproducible way to calculate an OR. As a result, we included 338
trials (365 outcomes and 487 comparisons) for quantitative analysis on the reported intervention
effect size bias assessment. The characteristics of trials with and without primary outcome change
are listed in Table 1.
On average, the reported intervention effect size in trials with primary outcome change was
found to be larger by 16% (pooled ROR, 0.84; 95% CI, 0.73-0.96) compared with those without
change. This result persisted after adjustment for potential confounders (ROR, 0.81; 95% CI,
0.71-0.93) and using the classification of the primary outcome change from reviewer 1 (unadjusted
ROR, 0.83; 95% CI, 0.73-0.95) and reviewer 2 (unadjusted ROR, 0.85; 95% CI, 0.75-0.97). Similarly,
we did not find material changes in other sensitivity analyses, with RORs ranging from 0.73 after
regarding the study weight as additional covariates rather than the weights in themixedmodel to
0.96 after excluding studies with multiple groups (Table 2).
SubgroupAnalyses
For multicenter trials, the ROR between changed and unchanged primary outcomes was 0.83 (95%
CI, 0.72-0.96). For studies assessing continuous outcomes, the corresponding result was 0.74 (95%
CI, 0.57-0.94). For trials using a superiority study design, the ROR between changed and unchanged
primary outcomes was 0.82 (95% CI, 0.71-0.94). Overestimation of the reported intervention effect
Figure 1. Flowchart of Article Selection
1488 Randomly selected 5% of the records by each year
624 Potentially relevant
559 Primary reports of clinical trials
389 Articles with trial registry (416 outcomes)
338 Articles for treatment effect size assessment
(365 outcomes and 487 comparisons)
29 749 Articles identified from search
28 810 Medline via PubMed
939 Embase via Ovid
864 Excluded based on the title and abstract
222 Not RCTs
283 Ancillary analysis
75 Feasibility pilot phase 1 trials
181 Study design protocol/analysis plan
102 System review or meta-analysis
1 Duplicate study
65 Excluded after reading the full text
52 Ancillary analysis
10 Not RCTs
1 Feasibility/pilot study
2 Design protocol
170 Excluded after comparing with online registry
4 Not registered
92 Registered after study end
74 Registered before study end
6 No primary outcome in registry
68 Unclear primary outcome descriptions
in registry
51 Excluded for availability of treatment effect size
22 Excluded due to no primary outcome reported
29 Unavailable data for effect size estimation
19 Skewed data
7 Cannot get data from figure
3 No SDs
RCTs indicates randomized clinical trials; SDs, standard
deviations.
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Table 1. Characteristics of Included Randomized Clinical TrialsWith andWithout Primary Outcome Change
With Available Effect Sizea
Characteristic
With Change
(n = 100)
Without Change
(n = 238) P Value
Year of publication, No. (%)
2011-2012 18 (18.0) 42 (17.6)
.93
2012-2013 20 (20.0) 49 (20.6)
2013-2014 23 (23.0) 57 (23.9)
2014-2015 27 (27.0) 55 (23.1)
2015-2016 12 (12.0) 35 (14.7)
ITT status, No. (%)
ITT 44 (44.0) 104 (43.7)
.02mITT 26 (26.0) 91 (38.2)
No ITT/unknown 30 (30.0) 43 (18.1)
Study design, No. (%)
Noninferiority 5 (5.0) 26 (10.9)
.09
Superiority 95 (95.0) 212 (89.1)
Use of placebo, No. (%)
Yes 29 (29.0) 83 (34.9)
.30
No 71 (71.0) 155 (65.1)
Sample size calculation, No. (%)
Not reported 5 (5.0) 14 (5.9)
.75
Reported 95 (95.0) 224 (94.1)
Trial centers, No. (%)
Multiple centers 71 (71.0) 185 (77.7)
.19
Single center 29 (29.0) 53 (22.3)
Randomization method, No. (%)
Cluster 9 (9.0) 8 (3.4)
.03
Individual 91 (91.0) 230 (96.6)
Comparison, No. (%)
2 Groups and single outcome 66 (66.0) 183 (76.9)
.05
2 Groups but multiple outcomes 3 (3.0) 12 (5.0)
Multiple groups and single outcome 28 (28.0) 36 (15.1)
Multiple groups and multiple outcomes 3 (3.0) 7 (2.9)
No. of outcomes, median (range) 1 (1-3) 1 (1-3) .96
No. of comparisons, median (range) 1 (1-8) 1 (1-10) .12
Sequence generation, No. (%)
Low risk 74 (74.0) 155 (65.1)
.11
Unclear risk 26 (26.0) 83 (34.9)
Allocation concealment, No. (%)
Low risk 62 (62.0) 128 (53.8)
.03High risk 2 (2.0) 0
Unclear risk 36 (36.0) 110 (46.2)
Masking of patients and personnel, No. (%)
Low risk 73 (73.0) 186 (78.2)
.15High risk 17 (17.0) 23 (9.7)
Unclear risk 10 (10.0) 29 (12.2)
Masking of outcome assessor, No./total No. (%)b
Low risk 92/108 (85.2) 208/257 (80.9)
.26High risk 9/108 (8.3) 13/257 (5.1)
Unclear risk 7/108 (6.5) 36/257 (14.0)
(continued)
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size among trials with primary outcome change could be observed among other subgroups, although
they did not all reach statistical significance. In addition, there was no evidence of an interaction
between different trial characteristics (eg, study design, multiple centers or single center, and type
of outcome) and the estimated intervention effects (Figure 2).
Table 1. Characteristics of Included Randomized Clinical TrialsWith andWithout Primary Outcome Change
With Available Effect Sizea (continued)
Characteristic
With Change
(n = 100)
Without Change
(n = 238) P Value
Incomplete outcome data, No./total No. (%)b
Low risk 65/108 (60.2) 179/257 (69.6)
.08High risk 12/108 (11.1) 29/257 (11.3)
Unclear risk 31/108 (28.7) 49/257 (19.1)
Type of outcome, No./total No. (%)b
Time to event 11/108 (10.2) 54/257 (21.0)
.94Binary 51/108 (47.2) 107/257 (41.6)
Continuous 46/108 (42.6) 96/257 (37.4)
Source of funding, No. (%)
Public funding 49 (49.0) 83 (34.9)
.03
Cofinanced 17 (17.0) 35 (14.7)
For-profit funding 26 (26.0) 106 (44.5)
Not funded 1 (1.0) 2 (0.8)
Not reported 7 (7.0) 12 (5.0)
Overall risk of bias, No. (%)
Low risk 33 (33.0) 68 (28.6)
.08High risk 27 (27.0) 45 (18.9)
Unclear risk 40 (40.0) 125 (52.5)
Odds ratio, median (range)c 0.57 (0.00-2.25) 0.79 (0.01-5.54) .01
Abbreviations: ITT, intent to treat; mITT, modified
intent to treat.
a Studies with no primary outcome and/or recalculable
data for treatment effect estimation are excluded.
b Numbers and percentages are based on number of
outcomes (n = 365).
c Based on number of comparisons (n = 487).
Table 2. Main and Sensitivity AnalysesWith ROR Between Randomized Clinical TrialsWith
andWithout Primary Outcome Changea
Analysis
No. of
Trials
No. of
Comparisons ROR (95% CI) P Value
Main Analysis
Unadjusted 338 487 0.84 (0.73-0.96) .01
Sensitivity Analysis
Adjustedb 338 487 0.81 (0.71-0.93) .002
Primary outcome change based on reviewer 1
assessment only
338 487 0.83 (0.73-0.95) .007
Primary outcome change based on reviewer 2
assessment only
338 487 0.85 (0.75-0.97) .02
Adjustedc 338 487 0.73 (0.60-0.89) .002
Exclusion of studies with time-to-event outcome 279 409 0.81 (0.69-0.95) .01
Exclusion of studies with binary outcomes 194 275 0.78 (0.65-0.93) .007
Exclusion of studies with continuous outcomes 209 290 0.88 (0.74-1.05) .16
Exclusion of low risk 238 348 0.77 (0.65-0.92) .005
Exclusion of high risk 266 393 0.81 (0.69-0.95) .008
Exclusion of unclear risk 173 233 0.95 (0.81-1.11) .59
Exclusion of multiple outcome 313 411 0.80 (0.70-0.92) .003
Exclusion of multiple groups 264 280 0.96 (0.83-1.11) .55
Exclusion of multiple outcome or multiple groups 249 250 0.94 (0.82-1.07) .36
Abbreviation: ROR, ratio of odds ratios.
a Analyses were based on 338 studies with available
effect size.
b Based on weightedmixedmodel with covariates of
deviation from intent-to-treat principle, study
design, trial centers, type of comparator,
randomizationmethod, type of outcome, source of
funding, and overall risk of bias.
c Based onmixedmodel with the same covariates as
in footnote b, plus inverse of variance.
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Discussion
Our cross-sectional study was a survey of contemporary trials that included a broad range of medical
conditions and interventions. We found that 33.4% of the sample had at least 1 primary outcome
inconsistency between registration and publication. Among studies for which we could calculate an
intervention effect, we demonstrated that trials with primary outcome change reported larger
intervention effect sizes. This finding remained even after adjustment for RoB items and other
potential bias (eg, deviation from ITT principle, multiple centers, and source of funding) and a series
of sensitivity analyses (eg, exclusion of studies with binary outcomes). Because we were unable to
include trials that either did not declare a primary outcome in the registry or did not register their
protocol, this studymay underestimate the true consequences of the practice of primary
outcome change.
Several studies have assessed the discrepancy rates between registered and published clinical
trial outcomes among specific clinical areas (eg, pain),17-22 journals (eg, general medical journals and
high-impact journals),5,23-25 or registry entries (eg, ClinicalTrials.gov).5,9,21,26 A systematic review of
studies up to 2014 that compared registered with reported primary outcomes demonstrated a
median 31% rate of discrepancies.7 We found a similar rate in our study (33.4%), although it was
lower than the 60% in recent study27 among 192 trials. These findings highlight this prevalent issue
after publication of the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement.28
Figure 2. Subgroup Analyses by Various Study Characteristics
0 1.51.0
ROR (95% CI)
0.5
P Value
for Interaction
Favors primary
outcome change
Favors no primary
outcome changeSubgroup
Overall
.15ITT status
.98
ITT
No. of Trials
338
148
117
73
31
307
19
319
256
82
226
112
17
321
61
150
133
135
203
101
72
166
mITT
no ITT/unknown
Study design
No. of Comparisons
188
487
188
111
37
450
29
458
378
109
293
194
29
458
78
212
197
181
306
139
94
254
ROR (95% CI)
0.95 (0.79-1.15)
0.84 (0.73-0.96)
0.77 (0.58-1.01)
0.85 (0.53-1.38)
1.17 (0.52-2.62)
0.82 (0.71-0.94)
0.98 (0.05-19.80)
0.84 (0.51-1.29)
0.83 (0.72-0.96)
0.81 (0.51-1.29)
0.85 (0.73-0.99)
0.75 (0.57-0.99)
0.02 (0.00-5.09)
0.83 (0.73-0.96)
0.76 (0.45-1.28)
0.83 (0.64-1.08)
0.74 (0.57-0.94)
0.86 (0.70-1.05)
0.79 (0.65-0.96)
1.06 (0.84-1.34)
0.76 (0.56-1.03)
0.74 (0.59-0.93)
Noninferiority
Sample Size .20
.85
.26
.59
.38
.33
.08
Superiority
No calculation reported
Reported
Trial centers
Multiple centers
Type of comparator
Single center
Active control
Placebo control
Randomization method
Cluster
Type of outcomea
Individual
Time to event
Binary
Continuous
Source of funding
High risk
Low risk
Overall risk of biasa
Low risk
High risk
Unclear risk
ITT indicates intent to treat; mITT, modified intent to treat; and ROR, ratio of odds ratios.
a Different outcomes could be observed within the same trial.
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Notably, our analysis found that the 2most common discrepancies were omission of registered
primary outcomes and inclusion of new unregistered outcomes, which have been repeatedly
reported in other studies.5,21,22,24,29-31 Unlike other studies that compared published outcomes with
those in the registry at the time of the search18,22,25,32,33 or used a specific function (eg, “History of
Changes” in the ClinicalTrials.gov archive site),9 our study attempted to identify all outcome changes
after the initial registration and excluded those registered after the end of the trial. This is because
comparison with the original registered outcome is more relevant in understanding the true
consequences of outcome switching on the validity of a clinical trial. However, we still observed high
rates of trial registration after study completion (92 of 559) and no primary outcome or unclear
primary outcome in the registry (74 of 559) in this survey of contemporary trials after the CONSORT
2010 Statement. Such poor quality of trial registration has been highlighted in previous
studies.24,27,32,34-36 Although due to our study design wewere unable to address the reasons for
primary outcome change, some possibilities need to be assessed in future studies, such as pressure
to publish positive results with public funding or high rates of nonpublication among industry-
sponsored trials with primary outcome change.
Our study is the first to date to quantify the consequences of primary outcome change on the
reported intervention effect size in individual RCTs. Some specific characteristics of a trial, such as
deviation from ITT principle,11,37 small sample size,38,39 concealment of allocation,40,41 and single
center,12 have been assessed in several meta-epidemiological studies. In general, various
components of inadequate trial methods are associated with imprecision in the estimated
intervention effects, but themagnitude and direction of the bias may vary depending on themedical
conditions examined, the definition of inadequate methods, and analytic methods.11,12,37-41 In our
study, we found that trials with discrepancies between registry and publication showmore beneficial
treatments than those without. Our results were robust to a series of supplementary adjusted
analyses to adjust for potential confounding factors that may contribute to statistical precision in
RCTs, as well as to sensitivity analyses to account for the classification of primary outcome change.
Our study is based on a large sample of individual RCTs rather than a meta-epidemiological
approach. The study was performed across a range of medical disciplines, registries, and types of
outcomes. Therefore, the trials included in our study are likely representative of a cross-section of the
general population, andwe believe that our results are generalizable tomultiple settings. To explore
the association of primary outcome change with the reported intervention effect size, we used
several analytic approaches, which gave consistent results.
Limitations
Some caveats should be recognized in our study. First, similar to other meta-epidemiological studies,
our studymainly used published information and compared it with records in registries or protocols
if necessary. Consequently, our results largely depended on the quality of reporting, which is often
unsatisfactory.42 Second, almost 40% (221 of 559) of trials could not be assessed due to unavailable
or insufficient information on primary outcomes from both articles and registries (n = 170) and
unavailability of treatment effect size estimates (n = 51). Together with the reported publication bias
(eg, trials sponsored by industry are less likely to be published), this probably led to an
underestimation of the proportion of trials with primary outcome change and their association with
the reported intervention effect size. Third, although the potential for selective reporting of primary
outcomes was discernible in published trials, we first extracted the adjusted treatment differences
and their SEs and then the unadjusted ones if there was no clear statement to specify which was the
primary analysis result. This is because few trials released their original protocol and statistical
analysis plan.
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Conclusions
Results of this study suggest that primary outcome change in RCTs is common and likely
overestimates intervention effects. Trial sponsors and investigators should register the primary
outcomes, justify changes (if they occur), and report the results accordingly. This will allow the reader
to critically appraise and interpret the trial results without bias. Reviewers and editors should
routinely use prospectively registered data to avoid changes in primary outcomes during peer review,
a practice that has been adopted by leading journals (eg, JAMA and BMJ). Readers and cliniciansmust
be cautious about interpreting trial results and should be aware that trials with primary outcome
change could lead to an overestimation of intervention effects.
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